Digital innovation is transforming how Alzheimer’s disease is detected and monitored in clinical trials. Together, Medidata Solutions and Cogstate are advancing this process through a unified CNS solution that pairs scientific expertise with robust eCOA tools to elevate data quality and rater experience. Learn more about how these science-backed, technology-enabled services are setting a new benchmark for Alzheimer’s disease trial success – meet with our teams during CTAD 2025 in San Diego! Schedule a meeting here: https://lnkd.in/g65dbM65
Cogstate
Biotechnology Research
Melbourne, Victoria 45,404 followers
Simplifying brain health measurement.
About us
The brain is central to every aspect of our lives, yet it isn’t monitored with the same consistency and proactivity as other vital signs. As a neuroscience technology company, we believe that better brain health insights lead to better brain health outcomes. That's why we're on a mission to democratize cognitive health by radically simplifying the way it is measured. For more than 20 years, we’ve proudly supported the research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and individuals around the world. We create easy to use digital tests that provide rapid, reliable, and science-backed results and offer solutions that support the highest fidelity measurements possible. We believe our team members should have flexibility as to how, when, and where they work. We work flexibly to support our global team, who mostly work from home––and offer opportunities for face-to-face collaboration at our offices in New Haven, Melbourne, and London. Our team members also have access to co-working spaces around the world.
- Website
-
http://www.cogstate.com
External link for Cogstate
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Melbourne, Victoria
- Type
- Public Company
- Founded
- 1999
- Specialties
- Cognitive Testing, Healthcare, Academic Research, Remote Testing, Alzheimer's Disease, Dementia, Rare Disease, Central Nervous System, Rater Training, Neuroscience, Concussion, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Mood Disorders, Schizophrenia, Oncology, Decentralized Clinical Trials, and Clinical Trials
Locations
-
Primary
Get directions
367 Collins St
Level 32
Melbourne, Victoria 3000, AU
-
Get directions
195 Church Street
4th Floor
New Haven, CT 06510, US
-
Get directions
1 Long Lane
Uncommon Borough
London, England SE1 4PG, GB
Employees at Cogstate
Updates
-
Congratulations to the team at Tisento Therapeutics on publishing this important work – it was a privilege for Cogstate scientists to be involved! Your dedication to understanding the lived experience of those with MELAS is making an impact in the field and ensuring that clinical trials are designed with patients’ voices at the center.
For those living with the rare mitochondrial disease MELAS, which symptoms and impacts are most important to address? That’s what we learned from listening to patients and clinicians in our MELAS interview study. Like many rare diseases, there is a lack of understanding of how MELAS affects patients’ daily lives, and importantly, how to design clinical trials to measure what matters most to those living with the disease. This groundbreaking work helped close that knowledge gap and laid the foundation for what we’re measuring in our ongoing Phase 2b PRIZM study. The MELAS interview study findings were recently published in the Journal of Patient-Reported Outcomes. Learn more: https://lnkd.in/e-CZCPPN #WeHearYou #MitochondrialDisease #RareDisease #ClinicalResearch #PRO #PatientReportedOutcomes
-
-
Caretakers are often unsung heroes. The countless hours driving to appointments, the long nights worrying about the future, and the days taken off work are all just the tip of the iceberg in the unending selfless service rendered in support of loved ones. Beyond the everyday activities, many caretakers also participate in clinical trials alongside their loved ones, offering insights that are vital in understanding the impact of treatments. Without question your contributions are improving outcomes for generations to come. From all of us at Cogstate, we thank you. #NFCMonth #CaregivingAroundTheClock #CaregivingHappens
-
Today, on Phelan-McDermid Syndrome (PMS) Awareness Day, let’s take a moment to recognize the strength and resilience of individuals and families affected by this rare neurodevelopmental disorder. At Cogstate, we’re grateful to be part of the broader community of researchers, clinicians and advocates working together to deepen our understanding and support research that brings us closer to meaningful progress for those living with PMS and other rare diseases. #PMSAD #EveryStoryShinesGreen #phelanmcdermidsyndrome #RareDiseaseAwareness
-
91% of U.S. adults own a smartphone [1] which opens the door for research teams to deliver more accessible, accurate, and representative cognitive testing in clinical trials through unsupervised, remote administration utilizing personal devices. Svenja Wacker, PhD (Neuropsychology Science Director) presented data at the 2025 ISCTM Spring Conference showcasing the strengths of the Cogstate Brief Battery as a valid option for remote, self-administered cognitive testing via smartphone. Learn more about this research and explore the data here: https://buff.ly/juxSbOg [1] Pew Research, 2024
-
-
The Clinical Dementia Rating (CDR) scale remains a cornerstone in dementia research, valued for its use of informant interviews to provide rich, contextual insight into cognitive function. However, its ability to detect meaningful change depends on rater expertise, rigorous training, and careful protocol planning. Our latest blog explores practical strategies to increase signal detection and ensure reliable outcomes in your Alzheimer’s disease studies. Read the blog: https://buff.ly/EA3sO8u
-
-
For years, Cogstate team members have laced up their sneakers to support the Alzheimer's Association #Walk2EndAlz. Even now as a fully remote company, we make time to come together, especially for causes that matter. Last weekend, our #CogstateCrew in North Carolina walked in honor of loved ones, friends, and the millions impacted by this disease. 💜 As a small way of supporting, Cogstate matches every dollar team members raise. We are honored to be part of the fight to #EndAlz.
-
-
For decades, the ADAS-Cog has been considered a gold standard in Alzheimer’s disease clinical trials and is one of the most widely used tools in clinical research for assessing cognitive function in Alzheimer’s patients. However, this legacy tool has limitations when it comes to meeting the scale and complexity of modern clinical trials. Explore insights from Cogstate’s scientific leadership about the key advantages, unique challenges, and considerations of utilizing the ADAS-Cog. Read the blog here 👉: https://buff.ly/pFXYoEQ
-
-
In a recent pharmaphorum article, Cogstate Chief Medical Officer, Kaycee Sink, MD, MAS, joined Paul O'Donohoe, Senior Director, eCOA Product and Science at Medidata Solutions to share insights about the evolution of Alzheimer’s disease clinical trials. Together they discussed trial design elements that are important for sponsor teams, the growing role of technology and wearables in data collection, and how sites and participants are adapting to the shifting landscape. Read the full article here: https://lnkd.in/eWt4erMx #Medidata #EndAlz #Alzheimersdisease
-
-
The Cogstate team was delighted to present CNS insights and connect with industry colleagues during the 5th Annual Nordic Innovation Day! Thanks to Lundbeck and Medidata Solutions for the invite to participate at this fantastic event.
-